Matthias Pinter

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy

João Incio, Hao Liu, Priya Suboj et al. · Cancer Discovery · 2016 · 465 citations

Medicine, Oncology, Pharmacology +17

The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

Wolfgang Sieghart, Florian Hucke, Matthias Pinter et al. · Hepatology · 2013 · 343 citations · Full text

Medicine, Oncology, Chemotherapy +16

Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

Thomas Reiberger, Gregor Ulbrich, Arnulf Ferlitsch et al. · Gut · 2012 · 335 citations · Full text

Medicine, Pharmacotherapy, Clinical Pharmacology +14